Martin Svaton1, Milada Zemanova2, Jana Skrickova3, Lenka Jakubikova3, Vitezslav Kolek4, Juraj Kultan4, Leona Koubkova5, Alzbeta Bejckova5, Frantisek Salajka6, Michal Hrnciarik6, Bohuslav Melichar7, David Vrana7, Marek Konecny8, Renata Chloupkova8, Milos Pesek9. 1. Department of Pneumology and Phthisiology, Charles University, Faculty of Medicine in Pilsen, Pilsen, Czech Republic svatonm@fnplzen.cz. 2. Department of Oncology, Charles University, First Faculty of Medicine in Prague, Prague, Czech Republic. 3. Department of Respiratory Diseases and TB, Faculty of Medicine, Masaryk University, and University Hospital, Brno, Czech Republic. 4. Department of Pneumology and Phthisiology, Palacky University, Faculty of Medicine and Dentistry, Olomouc, Czech Republic. 5. Department of Pneumology, Second Faculty of Medicine, Charles University Prague and Faculty Hospital Motol, Prague, Czech Republic. 6. Department of Pneumology, Charles University, Faculty of Medicine in Hradec Kralove, Prague, Czech Republic. 7. Department of Oncology, Palacky University, Faculty of Medicine and Dentistry, Olomouc, Czech Republic. 8. Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic. 9. Department of Pneumology and Phthisiology, Charles University, Faculty of Medicine in Pilsen, Pilsen, Czech Republic.
Abstract
AIM: To investigate potential associations between clinical and standard peripheral blood biomarkers and clinical outcome in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. PATIENTS AND METHODS: A total of 120 patients with advanced NSCLC treated at seven comprehensive cancer care centers were analyzed in this national retrospective study. Survival statistics were evaluated using the Kaplan-Meier method and Cox analysis. RESULTS: Among clinical parameters, histology was significantly associated with progression-free survival. Univariate Cox-proportional hazards model indicated prognostic and predictive role of a panel of laboratory parameters reflecting chronic inflammatory pattern (elevated neutrophil count, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, C-reactive protein and decrease in hemoglobin and albumin). Higher serum calcium concentration was also associated with nivolumab treatment effect. CONCLUSION: Tumor histology was the only clinical parameter predicting the outcome of nivolumab treatment. Among the laboratory parameters, our analysis identified a laboratory panel reflecting chronic inflammation as a potential predictive marker of nivolumab treatment. Copyright
AIM: To investigate potential associations between clinical and standard peripheral blood biomarkers and clinical outcome in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. PATIENTS AND METHODS: A total of 120 patients with advanced NSCLC treated at seven comprehensive cancer care centers were analyzed in this national retrospective study. Survival statistics were evaluated using the Kaplan-Meier method and Cox analysis. RESULTS: Among clinical parameters, histology was significantly associated with progression-free survival. Univariate Cox-proportional hazards model indicated prognostic and predictive role of a panel of laboratory parameters reflecting chronic inflammatory pattern (elevated neutrophil count, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, C-reactive protein and decrease in hemoglobin and albumin). Higher serum calcium concentration was also associated with nivolumab treatment effect. CONCLUSION: Tumor histology was the only clinical parameter predicting the outcome of nivolumab treatment. Among the laboratory parameters, our analysis identified a laboratory panel reflecting chronic inflammation as a potential predictive marker of nivolumab treatment. Copyright